Creative Planning Lowers Position in DENTSPLY SIRONA Inc. (NASDAQ:XRAY)

Creative Planning reduced its stake in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 16.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,715 shares of the medical instruments supplier’s stock after selling 1,085 shares during the period. Creative Planning’s holdings in DENTSPLY SIRONA were worth $371,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the stock. Kayne Anderson Rudnick Investment Management LLC increased its position in shares of DENTSPLY SIRONA by 4.3% in the first quarter. Kayne Anderson Rudnick Investment Management LLC now owns 673,830 shares of the medical instruments supplier’s stock valued at $42,074,000 after buying an additional 27,860 shares during the last quarter. LaFleur & Godfrey LLC purchased a new stake in DENTSPLY SIRONA during the first quarter valued at approximately $3,323,000. Gateway Investment Advisers LLC boosted its stake in DENTSPLY SIRONA by 8.4% in the second quarter. Gateway Investment Advisers LLC now owns 19,408 shares of the medical instruments supplier’s stock valued at $1,258,000 after buying an additional 1,499 shares during the period. BlackRock Inc. boosted its stake in DENTSPLY SIRONA by 3,103.7% in the first quarter. BlackRock Inc. now owns 13,891,329 shares of the medical instruments supplier’s stock valued at $867,376,000 after buying an additional 13,457,730 shares during the period. Finally, Schwab Charles Investment Management Inc. boosted its stake in DENTSPLY SIRONA by 3.1% in the first quarter. Schwab Charles Investment Management Inc. now owns 710,579 shares of the medical instruments supplier’s stock valued at $44,369,000 after buying an additional 21,456 shares during the period. Hedge funds and other institutional investors own 95.13% of the company’s stock.

Shares of DENTSPLY SIRONA Inc. (NASDAQ XRAY) opened at 52.85 on Friday. DENTSPLY SIRONA Inc. has a 52 week low of $52.73 and a 52 week high of $65.68. The company’s 50 day moving average price is $61.35 and its 200-day moving average price is $62.19. The firm’s market capitalization is $12.13 billion.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its earnings results on Wednesday, August 9th. The medical instruments supplier reported $0.65 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.65. The business had revenue of $992.70 million during the quarter, compared to analyst estimates of $1 billion. DENTSPLY SIRONA had a positive return on equity of 7.24% and a negative net margin of 20.57%. DENTSPLY SIRONA’s revenue for the quarter was down 2.9% compared to the same quarter last year. During the same period last year, the company earned $0.76 EPS. On average, equities research analysts expect that DENTSPLY SIRONA Inc. will post $2.69 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 13th. Shareholders of record on Friday, September 29th will be issued a dividend of $0.0875 per share. The ex-dividend date is Thursday, September 28th. This represents a $0.35 dividend on an annualized basis and a yield of 0.66%. DENTSPLY SIRONA’s payout ratio is currently -10.09%.

ILLEGAL ACTIVITY NOTICE: “Creative Planning Lowers Position in DENTSPLY SIRONA Inc. (NASDAQ:XRAY)” was reported by BNB Daily and is the property of of BNB Daily. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at https://www.baseball-news-blog.com/2017/08/19/creative-planning-cuts-stake-in-dentsply-sirona-inc-nasdaqxray-updated-updated.html.

Several research firms have recently commented on XRAY. Stifel Nicolaus reissued a “buy” rating and issued a $66.00 target price (down from $70.00) on shares of DENTSPLY SIRONA in a research note on Thursday, August 10th. HC Wainwright reissued a “buy” rating and issued a $68.00 target price (down from $74.00) on shares of DENTSPLY SIRONA in a research note on Monday, August 14th. UBS AG reissued a “neutral” rating and issued a $59.00 target price (down from $62.00) on shares of DENTSPLY SIRONA in a research note on Thursday, August 10th. Morgan Stanley lifted their target price on DENTSPLY SIRONA from $66.00 to $67.00 and gave the company an “overweight” rating in a research note on Thursday, August 10th. Finally, TheStreet cut DENTSPLY SIRONA from a “b” rating to a “c+” rating in a research note on Wednesday, August 9th. Three investment analysts have rated the stock with a sell rating, three have given a hold rating and eight have given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $66.25.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Institutional Ownership by Quarter for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply